Investigational — This vaccine is not yet approved for general use. Information is for educational purposes only. Participation in clinical trials requires enrolment at an authorised trial centre.
BNT122 (Autogene Cevumeran)
Also known as: RO7198457 · iNeST · Individualised Neoantigen Specific Therapy
BNT122 made headlines in 2023 when Nature published results showing that in pancreatic cancer — one of the deadliest cancers with a 12% 5-year survival rate — personalised mRNA vaccines generated tumour-reactive T cells in 8 of 16 patients (50%), and those 8 patients had significantly delayed disease recurrence compared to non-responders. Pancreatic cancer is notoriously immunologically 'cold' (few mutations, dense immunosuppressive stroma), making this result extraordinary. Developed by BioNTech's founder Uğur Şahin, the vaccine encodes up to 20 patient-specific neoantigens and is given after surgical resection of pancreatic cancer combined with the PD-L1 inhibitor atezolizumab.
What It Targets
Target Antigen
Patient-specific pancreatic tumour neoantigens (up to 20 per patient)
Cancers Targeted
How It Works
Tumour resection → whole-exome and RNA sequencing → neoantigen prediction and HLA-binding affinity modelling → up to 20 mRNA sequences encoding patient-specific neoantigens are synthesised and formulated in lipid nanoparticles → given with atezolizumab (anti-PD-L1 checkpoint inhibitor) to prevent T-cell exhaustion → generates both CD4+ and CD8+ T cells with high specificity for the patient's tumour → memory T cells patrol for recurrence. The approach aims to 'heat up' the cold pancreatic tumour microenvironment.
Key Trial Results
- Nature 2023: 8/16 patients (50%) developed neoantigen-reactive T cells — responders had significantly longer recurrence-free survival
- Median recurrence-free survival not yet reached in T-cell responders at 18-month follow-up (vs rapid recurrence in non-responders)
- 18-month recurrence-free survival: 67% in immunological responders vs ~17% in non-responders
- T-cell responses persisted to 18 months — suggesting durable immune memory
- Phase 2 expansion trial now enrolling pancreatic, colorectal, and other tumour types
- EU: developed at BioNTech's Mainz facility under EU Cancer Mission support
Regulatory Status & Availability
Approval Status
Phase 2 expansion ongoing. Landmark Nature paper (2023) accelerated development.
Estimated Availability
Phase 2 ongoing — potential availability 2027–2028 if trials succeed
Important Considerations
- Pancreatic cancer must be resectable (surgically removable) — not applicable to advanced/metastatic stage
- Only 50% of patients generated strong T-cell responses — predictors of response not yet defined
- Manufacturing time is 6–9 weeks — post-surgical recurrence window is tight
- Atezolizumab side effects: immune-related adverse events (pneumonitis, hepatitis, colitis)
- Still Phase 1/2 — efficacy and survival benefit need confirmation in larger Phase 3 trials
Research References
iOnco provides this information for educational purposes only. Cancer vaccine availability, trial eligibility, and access pathways change frequently. Always discuss vaccination decisions and clinical trial participation with your oncologist or healthcare provider.